1. Home
  2. WHG vs HURA Comparison

WHG vs HURA Comparison

Compare WHG & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westwood Holdings Group Inc

WHG

Westwood Holdings Group Inc

SELL

Current Price

$19.13

Market Cap

185.2M

Sector

Finance

ML Signal

SELL

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

SELL

Current Price

$1.83

Market Cap

160.5M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
WHG
HURA
Founded
1983
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
185.2M
160.5M
IPO Year
2002
2010

Fundamental Metrics

Financial Performance
Metric
WHG
HURA
Price
$19.13
$1.83
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $8.04
AVG Volume (30 Days)
13.8K
★ 212.4K
Earning Date
10-29-2026
11-13-2026
Dividend Yield
★ 3.13%
N/A
EPS Growth
★ 203.85
47.93
EPS
★ 0.25
N/A
Revenue
★ $97,762,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$76.56
★ N/A
Revenue Growth
★ 3.21
N/A
52 Week Low
$14.70
$0.41
52 Week High
$20.97
$3.43

Technical Indicators

Market Signals
Indicator
WHG
HURA
Relative Strength Index (RSI) 50.89 36.85
Support Level $18.58 $1.27
Resistance Level $20.13 $1.83
Average True Range (ATR) 0.52 0.10
MACD 0.01 -0.02
Stochastic Oscillator 53.15 19.23

Price Performance

Historical Comparison
WHG
HURA

About WHG Westwood Holdings Group Inc

Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its Advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States, and also has its presence in Canada.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: